<p>Selecting the starting dose of Glimepiride &amp; Pioglitazone should be based on the patient&#39;s current regimen of Pioglitazone and/or sulfonylurea. Those patients who may be more sensitive to antihyperglycemic drugs should be monitored carefully during dose adjustment. It is recommended that a single dose of Pioglitazone &amp; Glimepiride be administered once daily with the first main meal.<br />
<br />
<strong>Starting dose for patients currently on Glimepiride monotherapy:</strong>&nbsp;Based on the usual starting dose of Pioglitazone (15 mg or 30 mg daily), Pioglitazone &amp; Glimepiride may be initiated at 30 mg/2 mg or 30 mg/4 mg tablet strengths once&nbsp;daily, and adjusted after assessing&nbsp;adequacy of therapeutic response.<br />
<br />
<strong>Starting dose for patients currently on Pioglitazone monotherapy:</strong>&nbsp;Based on the usual starting doses of Glimepiride (1 mg or 2 mg once daily), and Pioglitazone 15 mg or 30 mg, Pioglitazone &amp; Glimepiride may be initiated at 30 mg/2 mg once daily, and adjusted after assessing adequacy of therapeutic response.<br />
<br />
<strong>Starting dose for patients switching from combination therapy of Pioglitazone plus Glimepiride as separate tablets</strong>: Pioglitazone &amp; Glimepiride may be initiated with 30 mg/2 mg or 30 mg/4 mg tablet strengths based on the dose of Pioglitazone and Glimepiride already being taken. Patients who are not controlled with 15 mg of Pioglitazone in combination with Glimepiride should be carefully monitored when switched to&nbsp; Pioglitazone &amp; Glimepiride.<br />
<br />
<strong>Starting dose for patients currently on a different sulfonylurea monotherapy or switching from combination therapy of Pioglitazone plus a different sulfonylurea:&nbsp;</strong>No exact dosage relationship exists between Glimepiride and the other sulfonylurea agents. Therefore, based on the maximum starting dose of 2 mg Glimepiride, Pioglitazone &amp; Glimepiride should be limited initially to a starting dose of 30 mg/2 mg once daily, and adjusted after assessing adequacy of therapeutic response.</p>